Abstract
The regulatory landscape of Hepatocellular Carcinoma (HCC) is increasingly understood through the lens of non-coding RNA networks. This study identifies a novel post-transcriptional regulatory mechanism: the hsa_circ_0001726/miR-140-3p/KRAS axis. Our findings demonstrate that this axis drives HCC progression and contributes significantly to lenvatinib resistance, offering a potential new target for precision oncology.
Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, particularly in China. While surgical and targeted therapies have improved, advanced-stage patients face poor prognoses due to high recurrence rates and the emergence of drug resistance. Recent research has highlighted circular RNAs (circRNAs) as critical regulators that act as "sponges" for microRNAs (miRNAs), thereby modulating the expression of oncogenic messenger RNAs (mRNAs). This study aims to map these complex competing endogenous RNA (ceRNA) networks to uncover the drivers of HCC aggressiveness and therapeutic failure.
Methods
This research utilized a dual-pronged approach combining high-throughput bioinformatics with rigorous experimental validation.
Bioinformatics Pipeline
Researchers integrated multiple datasets from the Gene Expression Omnibus (GEO), including GSE235991, GSE121714, and GSE216115, to identify differentially expressed circRNAs and miRNAs. Using tools like Cytoscape, they constructed a regulatory network comprising 34 circRNA-miRNA pairs and 194 miRNA-mRNA pairs.
Experimental Validation
Findings were validated using RT-qPCR on 133 patient tissue samples. Physical interactions within the axis were confirmed via dual-luciferase reporter assays and RNA pull-down experiments, proving that hsa_circ_0001726 binds to miR-140-3p, which in turn targets the KRAS oncogene.
Functional and Resistance Assays
To investigate drug resistance, the team developed lenvatinib-resistant HCC cell lines. Functional impacts were assessed through knockdown (siRNA) and overexpression experiments, monitoring changes in cell proliferation and migration.
Key Results
Expression and Survival Risk
Analysis revealed that hsa_circ_0001726 and KRAS are significantly upregulated in HCC tissues, while miR-140-3p is markedly downregulated. High expression of hsa_circ_0001726 was strongly correlated with advanced T-stage and poor overall survival. Multivariate Cox regression indicated that patients with high hsa_circ_0001726 expression face a 2.402-fold increased risk of death or recurrence (p=0.019).
The "Decoy" Mechanism and Lenvatinib Resistance
The study confirmed the ceRNA hypothesis: hsa_circ_0001726 acts as a decoy, sponging miR-140-3p and preventing it from suppressing KRAS. This "release of the brake" leads to uncontrolled tumor growth. Crucially, silencing hsa_circ_0001726 in drug-resistant cells significantly restored their sensitivity to lenvatinib, suggesting a pathway to overcome clinical resistance.
Discussion and Future Directions
While the hsa_circ_0001726/miR-140-3p/KRAS axis is a clear driver of HCC, the broader post-transcriptional landscape remains complex. Future work should focus on the structural biology of circRNA formation and degradation, as well as in vivo validation using animal models. Developing stable RNA-based therapeutics to target this axis remains a primary challenge for translating these findings into clinical practice.
Summary updated